Compare AADX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AADX | PGEN |
|---|---|---|
| Founded | 1900 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2026 | 2013 |
| Metric | AADX | PGEN |
|---|---|---|
| Price | $9.90 | $6.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $22.88 | $13.65 |
| AVG Volume (30 Days) | 1.9M | ★ 4.6M |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $36.93 | $2,365.68 |
| Revenue Next Year | $15.57 | $85.75 |
| P/E Ratio | ★ N/A | $220.17 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.31 | $3.04 |
| 52 Week High | $24.24 | $8.98 |
| Indicator | AADX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 36.29 |
| Support Level | N/A | $6.08 |
| Resistance Level | $13.03 | $7.44 |
| Average True Range (ATR) | 0.75 | 0.44 |
| MACD | 0.01 | -0.17 |
| Stochastic Oscillator | 6.98 | 2.37 |
Applied Aerospace & Defense Inc specializes in providing engineering and vertically integrated manufacturing solutions for space and defense technology companies. The company builds complex hardware for extreme operating environments, combining deep material science and IP-enabled process expertise with the ability to enable rapid prototyping, enhance new product development, and responsively scale production. The majority of the company's revenue is derived from the sales of Defense Aviation and Airborne Systems, followed by Space and Launch Systems, C5ISR and Precision Strike Systems.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.